1. Home /
  2. Biotechnology

Biotechnology

Pfizer Gains on Positive Children-Dermatitis Treatment Results

Pfizer Gains on Positive Children-Dermatitis Treatment Results

Shares of Pfizer rise after the company announces positive results in a late-stage, non-steroid trial of a treatment for chronic dermatitis, or eczema, in kids.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

Adaptive Biotechnologies Shares Double After IPO

Adaptive Biotechnologies Shares Double After IPO

Adaptive, aiming to use the genetics of the immune system to personalize treatments for individual patients, sees its shares nearly double after its IPO.

Biogen Could Rally in the Weeks Ahead

Biogen Could Rally in the Weeks Ahead

Buyers have returned in recent months and the stock could be ready to rise.

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

AbbVie's Allergan Deal Sets Up Another Trade In Big Biotech

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

Acer Plummets After FDA Declines to OK Rare Genetic Disorder Treatment

Acer Plummets After FDA Declines to OK Rare Genetic Disorder Treatment

Acer plummets toward a record low after the Food and Drug Administration declined to approve its treatment for a genetic disorder that can cause blood vessels to fatally rupture.

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Wall Street Voices Skepticism on AbbVie's Aggressive Allergan Acquisition

Despite the financial positivity, many analysts warn the deal could have hiccups ahead.

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015

PFE was ready to pay $160 billion until U.S. regulators blocked the deal.

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.